Exacerbations and Their Outcomes International (EXACOS International)

February 20, 2023 updated by: Joon Young Choi

Exacerbations and Their Outcomes International (EXACOS International): Burden of Severe Exacerbations of COPD and the Association Between Frequency of Severe Exacerbations and Clinical and Health-care Utilization Outcomes

The aim of this study is to quantify the burden of severe AECOPD in South Korea, by investigating the association between frequency of severe AECOPD and clinical and health-care utilization outcomes.

Study Overview

Status

Completed

Conditions

Detailed Description

  1. BACKGROUND AND RATIONALE Chronic obstructive pulmonary disease (COPD) is a common, progressive disease characterized by airflow obstruction which is not fully reversible. Acute exacerbations of COPD (AECOPD) are worsening of COPD symptoms (breathlessness, cough, and sputum volume and purulence) beyond normal day to day variation. Between 30-50% of patients with COPD experience at least one AECOPD per year [1]. Even a single moderate AECOPD increases risk of future multiple AECOPD events, starting a spiral of excessive disease progression and leading to an increased risk of death [2]. AECOPDs have also been associated with other clinical outcomes such as accelerated lung function decline [3,4].

    Studies have shown that AECOPDs are related to future AECOPDs, however, little is known about clinical burden and health care utilization in the COPD population [2, 5]. To date, most of published literature reports a combined category of moderate-severe exacerbations, typically stratifying patients as experiencing frequent (i.e. two or more events per patient-year) vs. infrequent (none or one) exacerbations.

    The aim of this study is to quantify the burden of severe AECOPD in South Korea, by investigating the association between frequency of severe AECOPD and clinical and health-care utilization outcomes.

    This study will help to understand the relationship between severe AECOPD and clinical and health care utilization burden in South Korea with no established health care databases.

  2. OBJECTIVES AND HYPOTHESES The objective is to quantify the burden of severe AECOPD by describing the clinical and health care utilization burden of AECOPD by frequency.

2.1 Primary Objectives

2.1 Primary Objectives & Hypothesises

  1. To estimate the frequency of severe AECOPD, in a COPD population
  2. To describe any time trends in the frequency of severe exacerbations throughout the study period (over a 2-year period)
  3. To describe lung function decline over time (FEV1)
  4. To quantify health care resource utilization by number of severe AECOPD over a 2-year period

2.2 Secondary Objective & Hypothesis

  1. Modified Medical Research Council (mMRC) dyspnea scale measured at time of the visit

    3. METHODOLOGY

    3.1 Study Design - General Aspects This study was based on the Korea COPD Subgroup Study (KOCOSS) database, constructed from a nationwide prospective cohort study-initiated in April 2012-that involved 54 medical centers in South Korea.

    During the patient visit, data was captured through the use of Case Report Forms (CRFs) by a doctor or trained nurse. After a baseline evaluation, patients were examined at 1-year follow-up.

    3.2 Study Population

    Inclusion criteria of the KOCOSS database is as follows:

    1) Age > 40 years; 2) those with post-bronchodilator (FEV1)/forced vital capacity (FVC) ≤ 70% of the normal predicted value.

    The following subpopulations of interest will be identified:

    • Patients with eosinophils ≥100cells/ul

    • Patients with a history of a comorbidity of special interest:

    - Any history of major cardiovascular comorbidity as recorded in the medical records: AMI, heart failure, stroke (+ MACE)

    - Any cardiovascular risk factor as recorded in the medical history: hypertension, diabetes - Any history of other major comorbidity: depression, anxiety, GERD, renal failure, etc.

    3.3 Study Period Data of COPD patients from April 2012 to 2021 will be extracted and analyzed

    4. VARIABLES AND EPIDEMIOLOGICAL MEASUREMENTS

    4.1 Exposures

    The main exposure for this study is severe exacerbation frequency. A severe exacerbation will be primarily defined as a hospitalization (with or without ICU) or an emergency department visit as a result of worsening of COPD symptoms. The number of severe AECOPD was counted at the initial visit in recall of previous 1-year events, and prospectively measured at 1-year follow up visit. The annual severe AECOPD frequency will be estimated in the 2 years (pre- and post- 1-year of initial visit), and divided by 2. This will guide the categorization of the severe AECOPD frequency. We expect the following categories:

    - 0 events

    - 1 severe event

    • 2 severe events
    • 3 severe events
    • >3 severe events

    The distribution of exacerbations across the entire 2 year period will also be described. In order to fully describe severe AECOPDs and their impact in disease progression, clinical burden, and healthcare costs the following outcomes will be measured:

    1) Clinical burden defined as change in lung function (FEV1) over time 2) Co-morbidities 3) Health care utilization burden will be defined accounting for:

    -number of emergency department visits

    -number of hospitalizations

    -number of ICU episodes

    5. STATISTICAL ANALYSIS PLAN

    5.1 Statistical Methods - General Aspects Summary statistics will be provided for the COPD population overall and by sub-populations noted above. Continuous measures will be described using means and standard deviations and categorical measures will be reported using numbers and proportions. Count variables will be expressed as rates per person-year. Groups will be compared using standard univariate statistical methods, including the chi-square test or the Fisher exact test for categorical variables and the analysis of variance test for continuous variables.

    5.2 Sample Size and Power Calculations No power calculations were performed as the objectives of this study are mostly descriptive in nature.

Study Type

Observational

Enrollment (Actual)

3477

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Gyeongki
      • Incheon, Gyeongki, Korea, Republic of, 21431
        • Incheon St. Mary's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

This study was based on the Korea COPD Subgroup Study (KOCOSS) database, constructed from a nationwide prospective cohort study-initiated in April 2012-that involved 54 medical centers in South Korea. It was designed to evaluate characteristics of COPD patients in South Korea.

Description

  • Inclusion Criteria:

    1. Over 40 years old South Korean COPD patients(Bronchodilator test results FEV1/FVC <0.7)
    2. COPD patients who complain of cough, sputum, dyspnea
    3. Unrelated smoking history
  • Exclusion Criteria:

    1. other disease like asthma patients which is similar to COPD symptoms.
    2. patients who is not suitable for pulmonary function test and communication
    3. myocardial infarction or cerebrovascular event within the previous 3 months
    4. pregnants
    5. patients who disagree with registration
    6. rheumatoid patients
    7. cancer patients(including metastatic cancer, leukemia, lymphoma)
    8. irritable bowel syndrome
    9. patients who use systemic steroids over 8 weeks due to other diseases except COPD

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the frequency of severe AECOPD
Time Frame: 10-year
To estimate the frequency of severe AECOPD, in a COPD population
10-year
time trends in the frequency of severe exacerbations
Time Frame: 2-year
To describe any time trends in the frequency of severe exacerbations throughout the study period (over a 2-year period)
2-year
lung function decline over time
Time Frame: 3-year
To describe lung function decline over time (FEV1)
3-year
health care resource utilization
Time Frame: 2-year
To quantify health care resource utilization by number of severe AECOPD over a 2-year period
2-year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2012

Primary Completion (Actual)

December 1, 2021

Study Completion (Actual)

December 1, 2021

Study Registration Dates

First Submitted

February 20, 2023

First Submitted That Met QC Criteria

February 20, 2023

First Posted (Actual)

March 2, 2023

Study Record Updates

Last Update Posted (Actual)

March 2, 2023

Last Update Submitted That Met QC Criteria

February 20, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • ESR-21-21659

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

IPD is not available due to restriction

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COPD

Clinical Trials on Severe exacerbation frequency

Subscribe